Truist analyst Tobey Sommer lowered the firm’s price target on Insperity (NSP) to $70 from $82 and keeps a Hold rating on the shares after its Q1 earnings miss and below-consensus guide. The firm is citing deteriorating SMB sentiment and risks of further healthcare issues, along with higher healthcare utilization, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NSP: